Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options. …

In vitro cancer cultures, including three-dimensional organoids, typically contain exclusively
neoplastic epithelium but require artificial reconstitution to recapitulate the tumor …

Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic
locations. The management of this disease poses a significant challenge because of the …

Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide versus …

Neuroendocrine tumors (NETs) comprise a broad family of tumors that may or may not be
associated with symptoms attributable to hormonal hypersecretion. The NCCN Clinical …

Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase
inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This …

The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations
for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland …

There have been significant developments in diagnostic and therapeutic options for patients
with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which …

Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over
conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should …

PURPOSE: This Phase II trial evaluated the toxicity, local control, and overall survival in
patients treated with sequential gemcitabine and linear accelerator–based single-fraction …